Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide vs Insulin Glargine in T2D (LEAD-5)
NCT00331851Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2006
- Primary completion
- Apr 2007
- Modality
- Peptides
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of liraglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Glycated Hemoglobin A1c at 26 weeks. Started May 2006; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00331851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00331851.